<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26282840</article-id>
      <article-id pub-id-type="pmc">4539859</article-id>
      <article-id pub-id-type="publisher-id">1086</article-id>
      <article-id pub-id-type="doi">10.1186/s12879-015-1086-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Development of fluconazole resistance in a series of <italic>Candida parapsilosis</italic> isolates from a persistent candidemia patient with prolonged antifungal therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Li</given-names>
          </name>
          <address>
            <email>zhangli19870711@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>Meng</given-names>
          </name>
          <address>
            <email>cjtcxiaomeng@aliyun.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Watts</surname>
            <given-names>Matthew R.</given-names>
          </name>
          <address>
            <email>watts.idmicro@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>He</given-names>
          </name>
          <address>
            <email>raulshiny@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>Xin</given-names>
          </name>
          <address>
            <email>fanxin12356@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kong</surname>
            <given-names>Fanrong</given-names>
          </name>
          <address>
            <email>kongfr_nk@yahoo.com.au</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Xu</surname>
            <given-names>Ying-Chun</given-names>
          </name>
          <address>
            <phone>+ 86-10-6915-9766</phone>
            <email>xycpumch@139.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 China </aff>
        <aff id="Aff2"><label/>Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730 China </aff>
        <aff id="Aff3"><label/>Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR &#x2013; Pathology West, University of Sydney, Westmead Hospital, Darcy Road, Westmead, Sydney, NSW 2145 Australia </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>340</elocation-id>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>8</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Zhang et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p><italic>Candida parapsilosis</italic> was the most common species causing candidemia in the 2010 China Hospital Invasive Fungal Surveillance&#xA0;Net (CHIF-NET) database. Compared to <italic>Candida albicans</italic>, the description of azole resistance and mechanisms in <italic>C. parapsilosis</italic> is very limited. We report a patient with <italic>C. parapsilosis</italic> candidemia over several months, due to a probable intravascular source, who developed fluconazole resistance after prolonged treatment.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>An 82&#xA0;year-old male had a hospital admission of approximately 1.5&#xA0;years duration. He was initially admitted with acute pancreatitis. Prior to succumbing to the illness, he developed candidemia and treated with three antifungal drugs for nearly 5&#xA0;months, at suboptimal doses and without source control. Following treatment, 6 blood cultures were still positive for <italic>C. parapsilosis</italic>. The last 2 strains were resistant to fluconazole (MICs 32&#xA0;&#x3BC;g/mL) and intermediate to voriconazole (MICs 0.5&#xA0;&#x3BC;g/mL). Microsatellite multilocus analysis indicated that the 6 isolates from the patient belonged to a single genotype. The first 4 isolates were susceptible to fluconazole (MICs 2&#xA0;&#x3BC;g/mL) and voriconazole (MICs 0.015-0.03&#xA0;&#x3BC;g/mL), which were slightly higher than susceptible control strains from other patients. Overexpression of <italic>MDR1</italic> genes were detected in the two resistant isolates, and this was associated with a homozygous mutation in <italic>MRR1</italic> genes (T2957C /T2957C), with the amino acid exchange L986P.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This case corroborates that the resistant <italic>C. parapsilosis</italic> isolates can emerge in the setting of complicated infections and the extensive use of antifungal agents, emphasizing the need for standardizing and improving the antifungal treatment as well as source control in the treatment of infection diseases.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>
          <italic>Candida parapsilosis</italic>
        </kwd>
        <kwd>Fluconazole resistance</kwd>
        <kwd>Persistent candidemia</kwd>
        <kwd>Antifungal treatment</kwd>
        <kwd>
          <italic>MDR1</italic>
        </kwd>
        <kwd>
          <italic>MRR1</italic>
        </kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p><italic>Candida parapsilosis</italic> is a significant clinical pathogen that can grow in total parenteral nutrition, form biofilms on catheters and other implanted devices, persist in the hospital environment and be nosocomially transmitted by hand carriage [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. In China, <italic>C. parapsilosis</italic> was the most common species causing candidemia in the 2010 China Hospital Invasive Fungal Surveillance&#xA0;Net (CHIF-NET) study [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>Azoles are the most commonly used drugs for the treatment of <italic>Candida</italic> infections. Besides species that show intrinsic resistance, such as <italic>Candida krusei</italic>, the acquisition of azole resistance, particularly after prolonged exposure and prophylactic overuse, is well described in <italic>Candida albicans</italic>, <italic>Candida tropicalis</italic>, <italic>Candida glabrata</italic> [<xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. However, the descriptions of azole resistance in <italic>C. parapsilosis</italic> are very limited [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>Constitutive overexpression of 2 types of multidrug efflux pumps, encoded by <italic>CDR1</italic> or <italic>MDR1</italic> genes is a major cause of resistance to azoles [<xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>]. Morschh&#xE4;user et al. found that gain of function mutations in <italic>MRR1</italic> genes cause constitutive <italic>MDR1</italic> overexpression in fluconazole-resistant <italic>C. albicans</italic> and <italic>C. dubliniensis</italic> [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>]. Similarly, the mutations in <italic>TAC1</italic>, a transcription factor regulating <italic>CDR</italic> genes, are responsible for the constitutive high-level expression of <italic>CDR</italic> genes [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Another common mechanism is the <italic>ERG11</italic> gene overexpression or acquisition of mutations, resulting in target enzyme up-regulation or reduced affinity to bind azoles [<xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>]. The mutations in <italic>UPC2</italic> are a frequent cause of <italic>ERG</italic> upregulation [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
      <p>We encountered a case of induced fluconazole resistance in <italic>C. parapsilosis</italic> from a patient with persistent candidemia due to a probable intravascular source in the Peking Union Medical College Hospital (PUMCH). Here we describe the case and explore the possible resistance mechanism.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>An 82&#xA0;year-old male was admitted to the PUMCH in December, 2008 with severe, acute pancreatitis. He was managed with mechanical ventilation and received parenteral nutrition, diuretics and anti-microbial therapy. His renal function deteriorated in the 11<sup>th</sup> week following hospitalization, he began haemodialysis, 3 times per week, through a left internal jugular venous catheter. In the 49<sup>th</sup> week, he developed a fever of 39&#xA0;&#xB0;C, and blood culture were collected. He was treated with empirical meropenem and his fever resolved after 3&#xA0;days. His blood culture were positive for <italic>C. parapsilosis</italic> after 7&#xA0;days, however, due to his clinical improvement he was not given any antifungal therapy (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). In the 52<sup>nd</sup> week, the left internal jugular venous catheter was removed, and an arteriovenous fistula was created in the forearm using a polytetrafluoroethylene (PTFE) graft to allow hemodialysis. In the 66<sup>th</sup> week, he became febrile and a sputum smear showed a large amount of yeast, with culture positive for <italic>C. glabrata</italic>. CT scan of the chest showed nodules in the right upper lobe and bilateral pleural effusion. He was treated for a pulmonary fungal infection, with fluconazole (100&#xA0;mg/day, renal dose adjusted) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). While still on the antifungal therapy, <italic>C. parapsilosis</italic> susceptible to fluconazole was isolated from blood culture in the 71<sup>st</sup> week following admission. In the subsequent 9&#xA0;weeks the patient had intermittent fevers. There were 4 other blood cultures positive for <italic>C. parapsilosis</italic>, consistent with an intravascular source of infection (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The final two isolates (PU123 and PU127) were resistant to fluconazole and had intermediate susceptibility to voriconazole.<fig id="Fig1"><label>Fig. 1</label><caption><p>The antifungal treatment course and isolated <italic>C. parapsilosis</italic> strains information of the patient. <sup><italic>a</italic></sup>Sputum smear showed a large amount of yeast and antifungal treatment was commenced. <sup><italic>b</italic></sup>The patient died of systemic invasive fungal infection and chronic renal failure</p></caption><graphic xlink:href="12879_2015_1086_Fig1_HTML" id="MO1"/></fig></p>
      <p>Antifungal treatment received by the patient and isolated strains are summarized in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. Due to fluconazole treatment failure, it was changed to intraconazole (100&#xA0;mg/day) in the 74<sup>th</sup> week. This was ceased in the 76<sup>th</sup> week and fluconazole was recommenced at a higher dose (200&#xA0;mg/day). As a possible source of infection, the synthetic arteriovenous fistula was removed in the 78<sup>th</sup> week. However, the candidemia persisted and in the 80<sup>th</sup> week caspofungin (50&#xA0;mg/day) was commenced.</p>
      <p>In the 81<sup>st</sup> week, the patient became comatosed (Glasogow Coma Scale 5) with hypertonia, a positive Babinski sign, and neck rigidity, indicative of central nervous system infection or metabolic encephalopathy. No further investigations were performed, as treatment was withdrawn following discussion with the patient&#x2019;s family. The patient died in the 82<sup>nd</sup> week of admission.</p>
      <sec id="Sec3">
        <title>Comparison with control isolates</title>
        <p>The use of the isolates in the present study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (No. S-263). We have obtained the writing consent from the control patients to publish the case report.</p>
        <p>There were 6 blood culture isolates from the patient described in the case study (patient 1). In addition, 6 isolates of <italic>C. parapsilosis</italic> obtained from the other patients (patients 2&#x2013;7) in the PUMCH during the hospitalization of patient 1 were studied for control purpose. Identification of <italic>C. parapsilosis</italic> was confirmed by DNA sequencing of the fungal internal transcribed spacer (ITS) region and the D1/D2 domain of the 28S rRNA gene, using a published protocol [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
        <p>Sensititre YeastOne YO10 broth microdilution susceptibility panels (TREK Diagnostic Systems, Westlake, Ohio) were used to test the susceptibility of <italic>C. parapsilosis</italic> to antifungal agents, according to a published protocol [<xref ref-type="bibr" rid="CR21">21</xref>]. For <italic>C. parapsilosis,</italic> the interpretation of fluconazole, voriconazole and three echinocandins susceptibilities was done in accordance with CLSI M27-S4 [<xref ref-type="bibr" rid="CR22">22</xref>]. Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> summarizes the <italic>in vitro</italic> susceptibility results of the 12 <italic>C. parapsilosis</italic> isolates. There was no significant difference in the drugs tested except for fluconazole and voriconazole. The isolates from patients 2&#x2013;7 were susceptible to fluconazole (MICs 0.25-0.5&#xA0;&#x3BC;g/mL) and voriconazole (MICs &#x2264;0.008&#xA0;&#x3BC;g/mL) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). For patient 1, isolates PU017, PU110, PU112 and PU116 were susceptible to fluconazole (MICs 2&#xA0;&#x3BC;g/mL) and voriconazole (MICs 0.015-0.03&#xA0;&#x3BC;g/mL), but with higher MICs than the other susceptible strains. Isolates PU123 and PU127 were resistant to fluconazole (MICs 32&#xA0;&#x3BC;g/mL) and had intermediate susceptibility to voriconazole (MICs 0.5&#xA0;&#x3BC;g/mL) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<italic>C. parapsilosis</italic> strains information, antifungal susceptibilities, microsatellite typing results and the <italic>MRR1</italic> gene mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Strain no.<sup>a</sup>
</th><th rowspan="2">Patient</th><th rowspan="2">Ward<sup>b</sup>
</th><th colspan="9">Susceptibility results by Sensititre YeastOne<sup>c</sup> (&#x3BC;g/mL)</th><th colspan="4">Multilocus genotype<sup>d</sup>
</th><th rowspan="2">Genotype<sup>e</sup>
</th><th rowspan="2">
<italic>MRR1</italic>
</th></tr><tr><th>FLC</th><th>VRC</th><th>ITC</th><th>POS</th><th>ANF</th><th>MCF</th><th>CAS</th><th>5FC</th><th>AMB</th><th>B5</th><th>CP1</th><th>CP4</th><th>CP6</th></tr></thead><tbody><tr><td>PU017</td><td>1</td><td>EGW</td><td>2</td><td>0.03</td><td>0.12</td><td>0.06</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/WT</td></tr><tr><td>PU110</td><td>1</td><td>EGW</td><td>2</td><td>0.03</td><td>0.12</td><td>0.06</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/WT</td></tr><tr><td>PU112</td><td>1</td><td>EGW</td><td>2</td><td>0.03</td><td>0.06</td><td>0.06</td><td>0.25</td><td>0.25</td><td>0.25</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/WT</td></tr><tr><td>PU116</td><td>1</td><td>EGW</td><td>2</td><td>0.03</td><td>0.06</td><td>0.06</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/WT</td></tr><tr><td>PU123</td><td>1</td><td>EGW</td><td>32</td><td>0.5</td><td>0.12</td><td>0.06</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/T2957C</td></tr><tr><td>PU127</td><td>1</td><td>EGW</td><td>32</td><td>0.5</td><td>0.12</td><td>0.06</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A</td><td>T2957C/T2957C</td></tr><tr><td>PU004</td><td>2</td><td>Outpatient</td><td>0.5</td><td>&#x2264;0.008</td><td>0.06</td><td>0.03</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.06</td><td>0.5</td><td>107/107</td><td>242/242</td><td>307/307</td><td>267/267</td><td>B</td><td>WT/WT</td></tr><tr><td>PU026</td><td>3</td><td>ICU</td><td>0.25</td><td>&#x2264;0.008</td><td>0.03</td><td>0.03</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.06</td><td>0.5</td><td>143/145</td><td>242/242</td><td>304/304</td><td>282/282</td><td>C</td><td>WT/WT</td></tr><tr><td>PU090</td><td>4</td><td>Medical ward</td><td>0.5</td><td>&#x2264;0.008</td><td>0.03</td><td>0.03</td><td>0.5</td><td>0.5</td><td>0.25</td><td>&#x2264;0.06</td><td>0.5</td><td>113/129</td><td>224/245</td><td>358/358</td><td>267/270</td><td>D</td><td>WT/WT</td></tr><tr><td>PU106</td><td>5</td><td>Surgical ward</td><td>0.5</td><td>&#x2264;0.008</td><td>0.06</td><td>0.03</td><td>0.5</td><td>0.25</td><td>0.12</td><td>0.06</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>291/291</td><td>A<sup>f</sup>
</td><td>WT/WT</td></tr><tr><td>PU108</td><td>6</td><td>EGW</td><td>0.5</td><td>&#x2264;0.008</td><td>0.06</td><td>0.03</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.12</td><td>0.5</td><td>115/129</td><td>242/248</td><td>364/385</td><td>267/267</td><td>E</td><td>WT/WT</td></tr><tr><td>PU131</td><td>7</td><td>Medical ward</td><td>0.5</td><td>&#x2264;0.008</td><td>0.03</td><td>0.015</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.12</td><td>0.5</td><td>109/109</td><td>242/242</td><td>307/307</td><td>288/288</td><td>F</td><td>WT/WT</td></tr><tr><td>ATCC&#xA0;22019</td><td>-</td><td>-</td><td>1</td><td>0.015</td><td>0.12</td><td>0.03</td><td>0.5</td><td>0.5</td><td>0.25</td><td>0.12</td><td>0.5</td><td>129/129</td><td>245/251</td><td>304/304</td><td>291/291</td><td>G</td><td>WT/WT</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>All strains were isolated from blood cultures</p><p>
<sup>b</sup>
<italic>EGW</italic> Emergency general ward</p><p>
<sup>c</sup>
<italic>FLC</italic> Fluconazole, <italic>VRC</italic> Voriconazole, <italic>ITC</italic> Itraconazole, <italic>POS</italic> Posaconazole, <italic>ANF</italic> Anidulafungin, <italic>MCF</italic>, Micafungin, <italic>CAS</italic> Caspofungin, <italic>5FC</italic> 5-Flucytosine, <italic>AMB</italic> Amphotericin B. Clinical breakpoints for susceptible, intermediate, and resistant for <italic>C. parapsilosis</italic>, respectively, were those of the CLSI M27-S4 for fluconazole (&#x2264;2/4/ &#x2265;8&#xA0;&#x3BC;g/mL); and for voriconazole (&#x2264;0.125/0.25/&#x2265;1&#xA0;&#x3BC;g/mL); and for anidulafungin, caspofungin, and micafungin (&#x2264;2/4/&#x2265;8&#xA0;&#x3BC;g/mL)</p><p>
<sup>d</sup>The numbers indicate the fragment size in base pairs of the different alleles obtained with the listed marker</p><p>
<sup>e</sup>The genotype was designated according to the different microsatellite typing results</p><p>
<sup>f</sup>The PU106 isolate yielded identical genotype with the isolates from patient 1</p></table-wrap-foot></table-wrap></p>
        <p>All the strains were genotyped using the highly polymorphic microsatellite markers, B5, CP1, CP4 and CP6 [<xref ref-type="bibr" rid="CR23">23</xref>]. Amplification reactions were performed as previously reported [<xref ref-type="bibr" rid="CR23">23</xref>]. The microsatellite multilocus genotypes allowed the differentiation of the 12 strains from 7 patients into 6 different genotypes. The 6 isolates from patient 1 involved a single genotype (genotype A). The strains isolated from control patients 2&#x2013;4 and 6, 7 were assigned to genotypes B to G based on the observed differences. Isolate PU106 from the control patient 5 showed the same pattern on microsatellite sequence analysis as the isolates from patient 1 and designated genotype A (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).</p>
        <p>Primers used for PCR amplification of <italic>MRR1, TAC1, UPC2,</italic> and <italic>ERG11</italic> genes were listed in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> (11). After alignment of the <italic>MRR1</italic> sequences from the 12 isolates, a single nucleotide mutation (T2957C/WT) was detected in PU017, PU110, PU112 and PU116 compared with the <italic>MRR1</italic> sequence of <italic>C. parapsilosis</italic> ATCC 22019 and the control strain with the same pattern on microsatellite typing, PU106 genotype A (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). This mutation results in the replacement of a leucine amino acid residue with a proline (L986P). In the PU123 and PU127 isolates from patient 1, mutations were found in both alleles (T2957C/T2957C). After alignment of <italic>TAC1, UPC2</italic>, and <italic>ERG11</italic> gene sequences from the 12 isolates, no mutation was found.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Sequences of primers used in genes sequencing</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Primer name</th><th>Primer sequence</th><th>Reference</th></tr></thead><tbody><tr><td>MRR1-F</td><td>5'-CCCTTTCTTCCGCAGATTTC-3'</td><td>11</td></tr><tr><td>MRR1-R</td><td>5'-CGTTGTAAAGATGGCGTGGT-3'</td><td/></tr><tr><td>TAC1-F</td><td>5'-AAGAGACCTACAGATAGTGC-3'</td><td/></tr><tr><td>TAC1-R</td><td>5'-CTTGAGATGCTGAGACATAT-3'</td><td/></tr><tr><td>UPC2-F</td><td>5'-TTCGTGATAGTTTTGGTGGTAG-3'</td><td>11</td></tr><tr><td>UPC2-R</td><td>5'-TTTCCTCCACCCCTATTGTAG-3'</td><td/></tr><tr><td>ERG11-F</td><td>5'-ATGGCATTAGTTGATTTAGCCCT-3'</td><td/></tr><tr><td>ERG11-R</td><td>5'-TCAGATTACACATGTATCTCTTT-3'</td><td/></tr></tbody></table></table-wrap></p>
        <p>Overnight <italic>C. parapsilosis</italic> cultures were diluted to an optical density at 600&#xA0;nm (OD<sub>600</sub>) of 0.2 in YPD medium and then incubated at 35&#xA0;&#xB0;C with shaking at 150&#xA0;rpm for additional 6&#xA0;h to mid-log phase. Total RNA was extracted from isolates grown in YPD medium using the Yeast RNAiso Reagent Kit (TaKaRa, Tokyo, Japan) and reverse transcribed to cDNA using the PrimeScript RT Reagent Kit (TaKaRa, Tokyo, Japan) according to the instructions of the manufacturer. The quantitative real-time RT-PCRs were performed in triplicate using the SsoFast EvaGreen supermix (Bio-Rad, Hercules, CA, USA) on a BioRad CFX96 system. ATCC 22019 were used as the control isolate. The primers used in this study were listed in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The <italic>ACT1</italic> gene was used as the endogenous control. The change in fold expression was obtained by calculating 2<sup>-&#x394;&#x394;<italic>CT</italic></sup>, and a change of 2.5 times was considered to be overexpressed [<xref ref-type="bibr" rid="CR26">26</xref>]. The 2 resistant isolates from patient 1 had higher expression levels of <italic>MRR1</italic> than the four susceptible isolates from patient 1 (PU123 10.5-fold and PU127 9.5-fold; Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). The 4 susceptible isolates showed higher expression levels (&gt;2.5 fold) than the controls. The <italic>MDR1</italic> expression was further increased in the resistant isolates (PU123 51.0-fold and PU127 39.4-fold). In contrast, the <italic>CDR1</italic>, <italic>UPC2</italic>, <italic>ERG11</italic> genes expression levels in the 2 azole-resistant isolates were not significantly different from the 4 susceptible isolates from patient 1 and the control isolates.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Sequences of primers used in quantitative real-time RT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Primer name</th><th>Primer sequence</th><th>Reference</th></tr></thead><tbody><tr><td>MRR1-F</td><td>5'-ACAATGGTCTGAGCAATGAA-3'</td><td>11</td></tr><tr><td>MRR1-R</td><td>5'-GGCAATACTGGTGATGGAA-3'</td><td/></tr><tr><td>MDR1-F</td><td>5'-TTCGTGATAGTTTTGGTGGTAG-3'</td><td>11</td></tr><tr><td>MDR1-R</td><td>5'-TGAACCTGGAGTGAATCTTGT-3'</td><td/></tr><tr><td>CDR1-F</td><td>5'-GCGTTTGACCATCGGAGTT-3'</td><td>24</td></tr><tr><td>CDR1-R</td><td>5'-TACCGCTGTTTGCGAATCT-3'</td><td/></tr><tr><td>UPC2-F</td><td>5'-ATTGGAGTGTGGGTATCTTCAT-3'</td><td>11</td></tr><tr><td>UPC2-R</td><td>5'-CCTTCGCCTTCTTCAGTTC-3'</td><td/></tr><tr><td>ERG11-F</td><td>5'-GGTTTACTTGTGTTTGCTCCT-3'</td><td>11</td></tr><tr><td>ERG11-R</td><td>5'-GTCCATAAGATACGGCTGAAC-3'</td><td/></tr><tr><td>ACT1-F</td><td>5'-ATGATAGAGTTGAAAGTAGTTTGGTCAATA-3'</td><td>25</td></tr><tr><td>ACT1-R</td><td>5'-ACTACTGCTGAAAGAGAAATTGTTAGAGAC-3'</td><td/></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Quantitative real-time RT-PCR analysis of <italic>MDR1</italic> (<bold>a</bold>)<italic>, MRR1</italic> (<bold>b</bold>)<italic>, CDR1</italic> (<bold>c</bold>)<italic>, ERG11</italic> (<bold>d</bold>) and <italic>UPC2</italic> (<bold>e</bold>) genes expression levels in the 6 isolates from patient 1 and 6 susceptible isolates from other patients. Each sample was processed in triplicate. Error bars show the standard deviations</p></caption><graphic xlink:href="12879_2015_1086_Fig2_HTML" id="MO2"/></fig></p>
        <p>In order to confirm that only <italic>MRR1</italic> and&#xA0;<italic>MDR1</italic> genes were overexpressed, we subcultured isolates in the presence of sub-inhibitory concentrations of fluconazole, and repeated the gene expression studies. Two susceptible isolates (PU017, PU116), the 2 resistant isolates (PU123 and PU127) from patient 1, 3 control isolates (PU090, PU106 and PU131) were subcultured. All the tested isolates and the control strain ATCC 22019 were firstly incubated at 37&#xA0;&#xB0;C for 4&#xA0;h in RPMI 1640 (Sigma, USA). Fluconazole was then added at a concentration of 1/2 MIC and the isolates were incubated for an additional 4&#xA0;h. RNA extraction and the quantitative real-time RT-PCRs were performed as the previous experiment in the present study.</p>
        <p>The 2 resistant isolates showed higher expression levels of <italic>MRR1</italic> than the other isolates (PU123 3.90-fold and PU127 3.99-fold; Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). The <italic>MDR1</italic> expression was also obviously increased in the resistant isolates (PU123 9.70-fold and PU127 9.01-fold). Similar to the previous experiment, the <italic>CDR1</italic>, <italic>UPC2</italic>, <italic>ERG11</italic> genes expression levels in the 2 azole-resistant isolates were not higher than other susceptible isolates.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Gene expression in the eight <italic>C. parapsilosis</italic> isolates cultured in the presence of fluconazole with concentrations of 1/2 MIC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Sample</th><th colspan="2">
<italic>MDR1</italic>
<sup><italic>b</italic></sup>
</th><th colspan="2">
<italic>MRR1</italic>
<sup><italic>b</italic></sup>
</th><th colspan="2">
<italic>CDR1</italic>
<sup><italic>b</italic></sup>
</th><th colspan="2">
<italic>ERG11</italic>
<sup><italic>b</italic></sup>
</th><th colspan="2">
<italic>UPC2</italic>
<sup><italic>b</italic></sup>
</th></tr><tr><th>Expression</th><th>Expression SEM</th><th>Expression</th><th>Expression SEM</th><th>Expression</th><th>Expression SEM</th><th>Expression</th><th>Expression SEM</th><th>Expression</th><th>Expression SEM</th></tr></thead><tbody><tr><td>ATCC22019<sup>a</sup>
</td><td>1.00</td><td>0.04</td><td>1.00</td><td>0.03</td><td>1.00</td><td>0.02</td><td>1.00</td><td>0.04</td><td>1.00</td><td>0.03</td></tr><tr><td>PU017</td><td>2.38</td><td>0.09</td><td>1.74</td><td>0.04</td><td>0.81</td><td>0.03</td><td>0.87</td><td>0.02</td><td>1.04</td><td>0.03</td></tr><tr><td>PU116</td><td>2.33</td><td>0.13</td><td>1.55</td><td>0.10</td><td>1.03</td><td>0.06</td><td>1.08</td><td>0.06</td><td>1.16</td><td>0.06</td></tr><tr><td>PU123</td><td>9.70</td><td>0.63</td><td>3.90</td><td>0.20</td><td>0.21</td><td>0.01</td><td>0.26</td><td>0.15</td><td>0.31</td><td>0.02</td></tr><tr><td>PU127</td><td>9.01</td><td>0.28</td><td>3.99</td><td>0.14</td><td>0.28</td><td>0.01</td><td>0.35</td><td>0.01</td><td>0.37</td><td>0.02</td></tr><tr><td>PU090</td><td>2.16</td><td>0.10</td><td>0.74</td><td>0.03</td><td>0.77</td><td>0.03</td><td>0.55</td><td>0.03</td><td>0.53</td><td>0.02</td></tr><tr><td>PU106</td><td>1.45</td><td>0.07</td><td>1.55</td><td>0.05</td><td>1.55</td><td>0.04</td><td>1.13</td><td>0.05</td><td>1.86</td><td>0.07</td></tr><tr><td>PU131</td><td>1.17</td><td>0.04</td><td>1.31</td><td>0.05</td><td>0.95</td><td>0.02</td><td>0.52</td><td>0.01</td><td>0.52</td><td>0.02</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>ATCC22019 isolates was used as control isolate, and was also cultured in the presence of 1/2 MIC of fluconazole</p><p>
<sup>b</sup>All the samples for each gene were tested in triplicate. The left column shows the mean value of expression, and the right column shows the Standard Error of Mean (SEM)</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec4" sec-type="discussion">
      <title>Discussion</title>
      <p>Compared to other <italic>Candida</italic> species, <italic>C. parapsilosis</italic> tends to be associated with higher MICs to echinocandins [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, the development of azole resistant <italic>C. parapsilosis</italic> has significant clinical implications, as multiazole- and multiechinocandin-resistant isolates would limit available treatment options [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition, there could be nosocomial transmission of resistant <italic>C. parapsilosis</italic> between vulnerable patient groups [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p>Microsatellite genotyping was consistent with fluconazole resistant developing in previously susceptible strains of <italic>C. parapsilosis</italic>. The 2 resistant patient-isolates (PU123 and PU127) overexpressed <italic>MRR1</italic> and <italic>MDR1</italic>. The <italic>MRR1</italic> overexpression was highly associated with mutation (T2957C), leading to the amino acid exchange, L986P. This indicates that the <italic>C. parapsilosis</italic> resistance to fluconazole was conferred by the increased expression of the <italic>MRR1</italic> transcription factor, which resulted in a concomitant overexpression of <italic>MDR1</italic>.</p>
      <p>The previous studies have demonstrated that a gain-of-function mutation in one <italic>MRR1</italic> allele results only in slightly decreased susceptibilities to the azoles and the loss of heterozygosity further increases drug resistance [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. A similar observation was made in the present study, where the patient isolates that were heterozygous <italic>MRR1</italic> (T2957C/WT) mutants showed slightly higher MICs than wild type strains (WT/WT). The last 2 isolates became homozygous (T2957C/T2957C) mutants and showed much higher MICs and overexpression of <italic>MDR1</italic>. While this mutation was the probable cause of the phenotypic resistance in this case, a mutagenesis study that demonstrated the development of resistance and increased gene expression in a previously sensitive organism would provide additional evidence.</p>
      <p>After repeating the experiment in which the strains were cultured in media containing fluconazole with concentrations of 1/2 MIC for each isolate, we confirmed that only <italic>MDR1</italic> and <italic>MRR1</italic> were overexpressed in 2 resistant isolates. However, <italic>MDR1</italic> expression did not increase as much as in the initial experiment. This may be related to different medium as well as all the isolates, including the control isolate ATCC22019, being exposed to fluconazole. The <italic>ERG11</italic> genes in resistant isolates were not overexpressed, even following to fluconazole. Similarly, Grossman et al. has sequenced the <italic>ERG11</italic> and <italic>MRR1</italic> genes in 30 fluconazole resistant <italic>C. parapsilosis</italic> isolates and 37 susceptible dose-dependent isolates, and found no isolate with both the <italic>MRR1</italic> and <italic>ERG11</italic> gene mutation [<xref ref-type="bibr" rid="CR28">28</xref>]. In most cases, phenotypes of resistance developed due to a combination of mechanisms, so the whole genome sequencing will be included in subsequent investigation.</p>
      <p>This case corroborates that the resistant <italic>C. parapsilosis</italic> isolates can emerge in the setting of complicated infections and the extensive use of antifungal agents. Patient 1 received fluconazole treatment for more than 3&#xA0;months. However, treatment was not instituted for the first candidemia and when fluconazole treatment was commenced it was initially at a lower dose because of chronic renal failure, and on the basis of sputum microscopy. In the previous studies, suboptimal fluconazole dosing has leaded to the development of resistance in <italic>Candida</italic> species [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In addition, itraconazole was used for 2&#xA0;weeks, when it is not recommended for invasive candidiasis [<xref ref-type="bibr" rid="CR30">30</xref>]. This highlights the need for standardization of antifungal treatment, in terms of drug selection, dose and duration [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
      <p>In this case, probable sources of the persistent candidemia were the intravenous hemodialysis catheter and the synthetic vascular graft. Vascular catheters have been regarded as the source in more than 50&#xA0;% of cases of <italic>C. parapsilosis</italic> candidemia and prompt removal of the catheter is recommended [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    </sec>
    <sec id="Sec5" sec-type="conclusions">
      <title>Conclusions</title>
      <p>This report described a case where fluconazole resistant <italic>C. parapsilosis</italic> emerged during prolonged antifungal treatment, with associated <italic>MDR1</italic> overexpression, which was related to a <italic>MRR1</italic> mutation (T2957C). Resistant <italic>C. parapsilosis</italic> has the potential to complicate the management of candidemia in vulnerable patient groups. This case illustrates the need for effective antifungal treatment, source control in the treatment of infection diseases.</p>
      <sec id="Sec6">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this Case report. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>LZ, MX, FK and YCX conceived and designed the experiments; LZ, HW and XF performed the experiment, contributed to the acquisition, analysis and interpretation of data. LZ, MW and FK wrote the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>This present study was supported by Innovation Fund of Peking Union Medical College (2012-1002-023) and Research Special Fund for Public Welfare Industry of Health (201402001). This study was selected for oral presentation at the 12<sup>th</sup> ASM Conference on Candida and Candidiasis in 2014, New Orleans, America.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trofa</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gacser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nosanchuk</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title><italic>Candida parapsilosis</italic>, an emerging fungal pathogen</article-title>
          <source>Clin Microbiol Rev</source>
          <year>2008</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>606</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1128/CMR.00013-08</pub-id>
          <pub-id pub-id-type="pmid">18854483</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Asbeck</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Clemons</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title><italic>Candida parapsilosis</italic>: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility</article-title>
          <source>Crit Rev Microbiol</source>
          <year>2009</year>
          <volume>35</volume>
          <issue>4</issue>
          <fpage>283</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="doi">10.3109/10408410903213393</pub-id>
          <pub-id pub-id-type="pmid">19821642</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barchiesi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Caggiano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Falconi</surname>
              <given-names>DFL</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Barbuti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scalise</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Outbreak of fungemia due to <italic>Candida parapsilosis</italic> in a pediatric oncology unit</article-title>
          <source>Diagn Microbiol Infect Dis</source>
          <year>2004</year>
          <volume>49</volume>
          <issue>4</issue>
          <fpage>269</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2004.03.011</pub-id>
          <pub-id pub-id-type="pmid">15313532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernandez-Castro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Arroyo-Escalante</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carrillo-Casas</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Moncada-Barron</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Alvarez-Verona</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hernandez-Delgado</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Torres-Narvaez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lavalle-Villalobos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Outbreak of <italic>Candida parapsilosis</italic> in a neonatal intensive care unit: a health care workers source</article-title>
          <source>Eur J Pediatr</source>
          <year>2010</year>
          <volume>169</volume>
          <issue>7</issue>
          <fpage>783</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-009-1109-7</pub-id>
          <pub-id pub-id-type="pmid">19957192</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shao</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study</article-title>
          <source>J Clin Microbiol</source>
          <year>2012</year>
          <volume>50</volume>
          <issue>12</issue>
          <fpage>3952</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.01130-12</pub-id>
          <pub-id pub-id-type="pmid">23035204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Forrest</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lepak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marchillo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lincoln</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and <italic>Candida albicans</italic></article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2006</year>
          <volume>50</volume>
          <issue>7</issue>
          <fpage>2374</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.01053-05</pub-id>
          <pub-id pub-id-type="pmid">16801415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barchiesi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Calabrese</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sanglard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Falconi</surname>
              <given-names>DFL</given-names>
            </name>
            <name>
              <surname>Caselli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giannini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Giacometti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gavaudan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scalise</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Experimental induction of fluconazole resistance in <italic>Candida tropicalis</italic> ATCC 750</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2000</year>
          <volume>44</volume>
          <issue>6</issue>
          <fpage>1578</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.44.6.1578-1584.2000</pub-id>
          <pub-id pub-id-type="pmid">10817712</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wingard</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Merz</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Rinaldi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Karp</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Saral</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Increase in <italic>Candida krusei</italic> infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole</article-title>
          <source>N Engl J Med</source>
          <year>1991</year>
          <volume>325</volume>
          <issue>18</issue>
          <fpage>1274</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199110313251803</pub-id>
          <pub-id pub-id-type="pmid">1669837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wingard</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Merz</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Rinaldi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Karp</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Saral</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Association of <italic>Torulopsis glabrata</italic> infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1993</year>
          <volume>37</volume>
          <issue>9</issue>
          <fpage>1847</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.37.9.1847</pub-id>
          <pub-id pub-id-type="pmid">8239594</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moudgal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Boikov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vazquez</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Multiechinocandin- and multiazole-resistant <italic>Candida parapsilosis</italic> isolates serially obtained during therapy for prosthetic valve endocarditis</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2005</year>
          <volume>49</volume>
          <issue>2</issue>
          <fpage>767</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.49.2.767-769.2005</pub-id>
          <pub-id pub-id-type="pmid">15673762</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Guida</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Synnott</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Amorim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pina-Vaz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Butler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional profiling of azole-resistant <italic>Candida parapsilosis</italic> strains</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2011</year>
          <volume>55</volume>
          <issue>7</issue>
          <fpage>3546</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.01127-10</pub-id>
          <pub-id pub-id-type="pmid">21518843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanglard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Odds</surname>
              <given-names>FC</given-names>
            </name>
          </person-group>
          <article-title>Resistance of <italic>Candida</italic> species to antifungal agents: molecular mechanisms and clinical consequences</article-title>
          <source>Lancet Infect Dis</source>
          <year>2002</year>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>73</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(02)00181-0</pub-id>
          <pub-id pub-id-type="pmid">11901654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morschhauser</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The genetic basis of fluconazole resistance development in <italic>Candida albicans</italic></article-title>
          <source>Biochim Biophys Acta</source>
          <year>2002</year>
          <volume>1587</volume>
          <issue>2&#x2013;3</issue>
          <fpage>240</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/S0925-4439(02)00087-X</pub-id>
          <pub-id pub-id-type="pmid">12084466</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfaller</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment</article-title>
          <source>Am J Med</source>
          <year>2012</year>
          <volume>125</volume>
          <issue>1 Suppl</issue>
          <fpage>S3</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjmed.2011.11.001</pub-id>
          <pub-id pub-id-type="pmid">22196207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morschhauser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>BlaB-Warmuth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Homayouni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <article-title>The transcription factor Mrr1p controls expression of the <italic>MDR1</italic> efflux pump and mediates multidrug resistance in <italic>Candida albicans</italic></article-title>
          <source>PLoS Pathog</source>
          <year>2007</year>
          <volume>3</volume>
          <issue>11</issue>
          <pub-id pub-id-type="doi">10.1371/journal.ppat.0030164</pub-id>
          <pub-id pub-id-type="pmid">17983269</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dunkel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Blass</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Morschhauser</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the multi-drug resistance regulator <italic>MRR1</italic>, followed by loss of heterozygosity, are the main cause of <italic>MDR1</italic> overexpression in fluconazole-resistant <italic>Candida albicans</italic> strains</article-title>
          <source>Mol Microbiol</source>
          <year>2008</year>
          <volume>69</volume>
          <issue>4</issue>
          <fpage>827</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06309.x</pub-id>
          <pub-id pub-id-type="pmid">18577180</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schubert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Morschhauser</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Gain-of-function mutations in the transcription factor <italic>MRR1</italic> are responsible for overexpression of the <italic>MDR1</italic> efflux pump in fluconazole-resistant <italic>Candida dubliniensis</italic> strains</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2008</year>
          <volume>52</volume>
          <issue>12</issue>
          <fpage>4274</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00740-08</pub-id>
          <pub-id pub-id-type="pmid">18809934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coste</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Karababa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ischer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bille</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sanglard</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title><italic>TAC1</italic>, transcriptional activator of <italic>CDR</italic> genes, is a new transcription factor involved in the regulation of <italic>Candida albicans</italic> ABC transporters <italic>CDR1</italic> and <italic>CDR2</italic></article-title>
          <source>Eukaryot Cell</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>6</issue>
          <fpage>1639</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1128/EC.3.6.1639-1652.2004</pub-id>
          <pub-id pub-id-type="pmid">15590837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coste</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ischer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morschhauser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Forche</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Selmecki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bille</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sanglard</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>A mutation in Tac1p, a transcription factor regulating <italic>CDR1</italic> and <italic>CDR2</italic>, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in <italic>Candida albicans</italic></article-title>
          <source>Genetics</source>
          <year>2006</year>
          <volume>172</volume>
          <issue>4</issue>
          <fpage>2139</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1534/genetics.105.054767</pub-id>
          <pub-id pub-id-type="pmid">16452151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silver</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Role of <italic>Candida albicans</italic> transcription factor Upc2p in drug resistance and sterol metabolism</article-title>
          <source>Eukaryot Cell</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>6</issue>
          <fpage>1391</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1128/EC.3.6.1391-1397.2004</pub-id>
          <pub-id pub-id-type="pmid">15590814</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfaller</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Chaturvedi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Diekema</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Ghannoum</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Holliday</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Killian</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Messer</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Miskov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramani</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin</article-title>
          <source>J Clin Microbiol</source>
          <year>2008</year>
          <volume>46</volume>
          <issue>7</issue>
          <fpage>2155</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.00493-08</pub-id>
          <pub-id pub-id-type="pmid">18463213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="other">Clinical and Laboratory Standards Institute.&#xA0;Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement&#xA0;M27-S4. CLSI, wayne, PA, USA, 2012.</mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sabino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rosado</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Clemons</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Pais</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>New polymorphic microsatellite markers able to distinguish among <italic>Candida parapsilosis</italic> sensu stricto isolates</article-title>
          <source>J Clin Microbiol</source>
          <year>2010</year>
          <volume>48</volume>
          <issue>5</issue>
          <fpage>1677</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.02151-09</pub-id>
          <pub-id pub-id-type="pmid">20220157</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Berkow E, Manigaba K, Wanamaker E, Barker K, Caudle K, Rogers PD. Molecular Mechanisms of Multidrug Resistance in <italic>Candida parapsilosis</italic>. Poster. the 12th American Society for Microbiology (ASM) Conference,&#xA0;USA, 2014.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossignol</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Logue</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Grenon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lowndes</surname>
              <given-names>NF</given-names>
            </name>
            <name>
              <surname>Butler</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional response of <italic>Candida parapsilosis</italic> following exposure to farnesol</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2007</year>
          <volume>51</volume>
          <issue>7</issue>
          <fpage>2304</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.01438-06</pub-id>
          <pub-id pub-id-type="pmid">17684006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of azole resistance in 52 clinical isolates of <italic>Candida tropicalis</italic> in China</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2013</year>
          <volume>68</volume>
          <issue>4</issue>
          <fpage>778</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dks481</pub-id>
          <pub-id pub-id-type="pmid">23221625</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perlin</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Resistance to echinocandin-class antifungal drugs</article-title>
          <source>Drug Resist Updat</source>
          <year>2007</year>
          <volume>10</volume>
          <issue>3</issue>
          <fpage>121</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1016/j.drup.2007.04.002</pub-id>
          <pub-id pub-id-type="pmid">17569573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Cleveland</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lockhart</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Molecular Mechanisms of Fluconazole Resistance in <italic>Candida parapsilosis</italic> Isolates from a U.S. Surveillance System</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2015</year>
          <volume>59</volume>
          <issue>2</issue>
          <fpage>1030</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.04613-14</pub-id>
          <pub-id pub-id-type="pmid">25451046</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Yau</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lasco</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Weston</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Salazar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Garey</surname>
              <given-names>KW</given-names>
            </name>
          </person-group>
          <article-title>Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible <italic>Candida</italic> species in hospitalized patients with candidemia</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2012</year>
          <volume>56</volume>
          <issue>6</issue>
          <fpage>3239</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00019-12</pub-id>
          <pub-id pub-id-type="pmid">22411611</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marchetti</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Antifungal therapeutic drug monitoring: established and emerging indications</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2009</year>
          <volume>53</volume>
          <issue>1</issue>
          <fpage>24</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00705-08</pub-id>
          <pub-id pub-id-type="pmid">18955533</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pappas</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Rex</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Sobel</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Filler</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Dismukes</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
          <article-title>Guidelines for Treatment of Candidiasis</article-title>
          <source>Clin Infect Dis</source>
          <year>2004</year>
          <volume>38</volume>
          <issue>2</issue>
          <fpage>161</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1086/380796</pub-id>
          <pub-id pub-id-type="pmid">14699449</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfaller</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Diekema</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Gibbs</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Newell</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Finquelievich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wadula</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Geographic and temporal trends in isolation and antifungal susceptibility of <italic>Candida parapsilosis</italic>: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005</article-title>
          <source>J Clin Microbiol</source>
          <year>2008</year>
          <volume>46</volume>
          <issue>3</issue>
          <fpage>842</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.02122-07</pub-id>
          <pub-id pub-id-type="pmid">18199791</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
